The invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex attached to a substrate. Generally, methods of the invention comprise the use of a dual-anchored primer/target nucleic acid duplex or stabilizing molecule.
Completion of the human genome has paved the way for important insights into biologic structure and function. Knowledge of the human genome has given rise to inquiry into individual differences, as well as differences within an individual, as the basis for differences in biological function and dysfunction. For example, single nucleotide differences between individuals, called single nucleotide polymorphisms (SNPs), are responsible for dramatic phenotypic differences. Those differences can be outward expressions of phenotype or can involve the likelihood that an individual will get a specific disease or how that individual will respond to treatment. Moreover, subtle genomic changes have been shown to be responsible for the manifestation of genetic diseases, such as cancer. A true understanding of the duplexities in either normal or abnormal function will require large amounts of specific sequence information.
An understanding of cancer also requires an understanding of genomic sequence duplexity. Cancer is a disease that is rooted in heterogeneous genomic instability. Most cancers develop from a series of genomic changes, some subtle and some significant, that occur in a small subpopulation of cells. Knowledge of the sequence variations that lead to cancer will lead to an understanding of the etiology of the disease, as well as ways to treat and prevent it. An essential first step in understanding genomic duplexity is the ability to perform high-resolution sequencing.
Various approaches to nucleic acid sequencing exist. One conventional way to do bulk sequencing is by chain termination and gel separation, essentially as described by Sanger et al., Proc. Natl. Acad. Sci., 74(12): 5463–67 (1977). That method relies on the generation of a mixed population of nucleic acid fragments representing terminations at each base in a sequence. The fragments are then run on an electrophoretic gel and the sequence is revealed by the order of fragments in the gel. Another conventional bulk sequencing method relies on chemical degradation of nucleic acid fragments. See, Maxam et al., Proc. Natl. Acad. Sci., 74: 560–564 (1977). Finally, methods have been developed based upon sequencing by hybridization. See, e.g., Drmanac, et al., Nature Biotech., 16: 54–58 (1998).
Bulk sequencing techniques are not useful for the identification of subtle or rare nucleotide changes due to the many cloning, amplification and electrophoresis steps that complicate the process of gaining useful information regarding individual nucleotides. The ability to sequence and gain information from single molecules obtained from an individual patient is the next milestone for genomic sequencing. As such, research has evolved toward methods for rapid sequencing, such as single molecule sequencing technologies.
There have been many proposals to develop new sequencing technologies based on single-molecule measurements, generally either by observing the interaction of particular proteins with DNA or by using ultra high resolution scanned probe microscopy. See, e.g., Rigler, et al., DNA-Sequencing at the Single Molecule Level, Journal of Biotechnology, 86(3): 161 (2001); Goodwin, P. M., et al., Application of Single Molecule Detection to DNA Sequencing. Nucleosides & Nucleotides, 16(5–6): 543–550 (1997); Howorka, S., et al., Sequence-Specific Detection of Individual DNA Strands using Engineered Nanopores, Nature Biotechnology, 19(7): 636–639 (2001); Meller, A., et al., Rapid Nanopore Discrimination Between Single Polynucleotide Molecules, Proceedings of the National Academy of Sciences of the United States of America, 97(3): 1079–1084 (2000); Driscoll, R. J., et al., Atomic-Scale Imaging of DNA Using Scanning Tunneling Microscopy. Nature, 346(6281): 294–296 (1990). Unlike conventional sequencing technologies, their speed and read-length would not be inherently limited by the resolving power of electrophoretic separation. Other methods proposed for single molecule sequencing include detecting individual nucleotides as they are incorporated into a primed template, i.e., sequencing by synthesis.
While single molecule techniques have several advantages, implementation has been problematic. For example, the reproducibility and accuracy of many single molecule techniques rely upon the stability of a primer/target nucleic acid duplex attached to a solid substrate. However, incomplete binding of the primer to the template, disengagement of the primer from the template and disengagement of the duplex from the substrate are frequent occurrences in such single molecule techniques.
Accordingly, there is a need in the art for methods and devices for sequencing generally, and single molecule sequencing in particular, including methods for stabilizing a target nucleic acid for sequence determination.
The invention generally provides methods and surfaces for nucleic acid sequencing comprising stabilized primer/target nucleic acid duplexes on a surface. Methods of the invention generally contemplate the use of a primer/target nucleic acid duplex in which each of the primer and the template contain a molecule having a binding partner on the substrate. The primer/target is stabilized on the surface by binding of both the primer and the template to the surface. Binding pairs for use in the invention are any molecular pair that can be bound to a surface and attached to a nucleic acid. Some examples of preferred pairs include ligand/receptor, affinity pairs, antigen/antibody, and carbohydrate/lectin. For example, biotin/streptavidin, digoxigenin/anti-digoxigenin, and dinitrophenol/anti-dinitrophenol perform well in the invention. Other pairs are apparent to the skilled artisan based upon the description of the invention provided below.
According to the invention, the primer contains a member of a binding pair at its 5′ terminus, and the template contains a member of a binding pair at its 3′ terminus or the primer contains a member of a binding pair at its 3′ terminus and the template contains a member of a binding pair at its 5′ terminus. Thus, the primer hybridizes to the template, and the two attached binding pair members are oriented to bind to their respective mates on the surface.
The template and primer may contain the same type or species of binding pair or they may contain separate types or species. Binding may occur to a single species of binding partner or to separate members of the same species. For example, in one embodiment, both the template and the primer are bioinylated at opposite ends oriented to the surface (i.e., one at the 3′ end and one at the 5′ end) and the two biotin molecules adhere to the same streptavidin molecule (which has capacity to bind four biotins) on the surface. Alternatively, the two biotins adhere to separate streptavidin molecules spaced closely together on the surface. In another embodiment, the primer is attached to a member of a first binding pair and the template is attached to a member of a second binding pair. Upon hybridization, the first member attaches to its mate on the surface, and the second member attaches to its separate mate on the surface. In either embodiment, the combination of two separate mating pairs reduces loss of the hybrid due to either the template or the primer dissociating. It is apparent to the skilled artisan based upon this disclosure that any combination of binding pairs works to stabilize hybrid binding to a surface. For example, template and primer may have attached separate species of binder that, although distinct, bind to the same surface-bound mate.
The invention comprises methods for sequencing nucleic acids using stabilized, support-bound primer/template hybrids as described above. In a preferred embodiment, methods of the invention comprise template-dependent sequencing by synthesis using a polymerase capable of adding nucleotides to the primer in a template-dependent fashion. The invention is particularly useful for single molecule nucleic acid sequencing in which primer/template duplex is attached to a substrate such that the duplex is individually optically resolvable. Individual strand sequence is determined by detecting ordered template-dependent nucleotide incorporation into the primer and compiling a sequence of the template based upon the order of incorporated nucleotides.
The invention also provides for the use of a stabilizing molecule in template-dependent sequencing. Stabilizing molecules useful in the invention include, for example, locked nucleic acid (“LNA”) analogs and peptide nucleic acid (“PNA”) analogs. Generally, a stabilizing molecule increases the affinity and specificity of the primer/target nucleic acid bond, and increases the melting temperature of the primer/target nucleic acid duplex or the specificity of incorporation of a nucleotide into the primer in a sequencing by synthesis reaction. An example of a locked nucleic acid is shown in
Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer. Depending on the characteristics of the target nucleic acid, a DNA polymerase, an RNA polymerase, or a reverse transcriptase can be used. According to one aspect of the invention, a thermophilic polymerase is used, such as ThermoSequenase®, 9° N™, Taq, Tfl, Tth, Tli, Therminator, or Pfu. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius. A preferred polymerase is a Klenow fragment having reduced 3′-5′ exonuclease activity.
Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
Nucleotides for primer addition according to the invention preferably comprise a detectable label. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.
In one embodiment, fluorescence resonance energy transfer (FRET) is used to determine the base type incorporated into the primer. Fluorescence resonance energy transfer in the context of sequencing is described generally in Braslavasky et al., Sequence Information can be Obtained from Single DNA Molecules, Proc. Nat'l Acad. Sci., 100: 3960–3964 (2003), incorporated by reference herein. Essentially, in one embodiment, a donor fluorophore is attached to either the primer, polymerase, or template. Nucleotides added for incorporation into the primer comprise an acceptor fluorophore that is activated by the donor when the two are in proximity. Activation of the acceptor causes it to emit a characteristic wavelength of light and also quenches the donor. In this way, incorporation of a nucleotide in the primer sequence is detected by detection of acceptor emission. Of course, nucleotides labeled with a donor fluorophore also are useful in methods of the invention; FRET-based methods of the invention only require that a donor and acceptor fluorophore pair are used, a labeled nucleotide may comprise one fluorophore and either the template or the polymerase may comprise the other. Such labeling techniques result in a coincident fluorescent emission of the labels of the nucleotide and the labeled template or polymerase, or alternatively, the fluorescent emission of only one of the labels.
In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
Preferred substrates include glass, silica, and others with the optical properties described herein. Surfaces for sequencing according to the invention may be coated with, for example, an epoxide, polytetrafluoroethylene or a derivative of polytetrafluoroethylene, such as silanized polytetrafluoroethylene, a polyelectrolyte multilayer (PEM), or the equivalent.
Primers useful in the invention hybridize to template in a manner that allows template-dependent sequencing-by-synthesis. Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. The invention also teaches the use of stabilizing molecules used in connection with the primer or the primer/template duplex, such as locked nucleic acid or peptide nucleic acid analogs. According to the invention, the melting temperature of the primer/target nucleic acid duplex may be increased from about 3° to about 8° Celsius per PNA or LNA base included in the primer. In one embodiment, the primer comprises a locked nucleic acid base on its 3′ terminus. The primer may comprise any portion of PNA or LNA bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total nucleic acid residues in the primer. The PNA or LNA bases may be consecutive in the primer or may be interspersed throughout the primer. In a preferred embodiment, PNA or LNA bases are spaced apart at a distance of at least one turn of the helix when the primer is hybridized to template. The use of LNA or PNA analogs allows primers to be shorter than would be the case to achieve similar melting temperatures using conventional nucleic acids. According to one embodiment of the invention, the primer comprises fewer than 25 nucleic acids.
Methods of the invention are suitable for de novo sequencing, re-sequencing, sequence analysis, DNA fingerprinting, polymorphism identification, for example single nucleotide polymorphisms (SNP) detection, as well as for research and clinical applications in genetics. Applied to RNA sequences, methods according to the invention also identify alternate splice sites, enumerate copy number, measure gene expression, identify unknown RNA molecules present in cells at low copy number, annotate genomes by determining which sequences are actually transcribed, determine phylogenic relationships, and elucidate differentiation of cells. Methods and surfaces of the invention are useful in diagnostic, therapeutic, prognostic (including drug selection), and developmental applications.
As will be appreciated by one skilled in the art, individual features of the invention may be used separately or in any combination. A detailed description of embodiments of the invention is provided below. Other embodiments of the invention are apparent upon review of the detailed description that follows.
The results of single molecule sequencing are influenced by the stability of substrate-bound primer/target nucleic acid duplexes. Typically, single molecule sequencing comprises repeated single base extension reactions followed by one or more wash steps. Sequencing occurs on single strands spaced apart such that each strand is individually optically resolvable. Spatial and temporal stability of the individual strands are important in order to preserve the integrity of the sequencing process. One way in which the spatial stability of a single molecule array can be disrupted is if the template and/or primer become disassociated with the surface. For example, template/primer hybridization is a dynamic process. Primer melts off template at a low, but detectable rate. Once melting occurs, at least some portion of primer will be unavailable to re-anneal with template. That is not necessarily a problem in a bulk sequencing reaction in which numerous copies of each template are available for sequencing. However, in single molecule sequencing, in which individual strands are sequenced, loss of any strand can have a significant effect on the result. Methods and surfaces of the invention address this problem by placing stabilizing binding partners on each of the template and primer and, optionally, utilizing stabilizing molecules that confer an increased melting temperature on the primer/template hybrid.
I. General Considerations
Substrates
Generally, a substrate may be made of any suitable material that allows single molecules to be individually optically resolvable. Substrates for use according to the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped. Appropriate substrates include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silica, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.
Preferably, a substrate used according to the invention includes a biocompatible or biologically inert material that is transparent to light and optically that (i.e., with a minimal micro-roughness rating). Specially manufactured, or chemically derivatized, low background fluorescence substrates (e.g., glass slides) are also contemplated according to the invention. Substrates may be prepared and analyzed on either the top or bottom surface of the planar substrate (i.e., relative to the orientation of the substrate in the detection system).
The invention also includes three-dimensional substrates such as spheres, tubes (e.g., capillary tubes), microwells, microfluidic devices, or any other structure suitable for anchoring a nucleic acid. For example, a substrate can be a microparticle, a bead, a membrane, a slide, a plate, a micromachined chip, and the like. Substrates can include planar arrays or matrices capable of having regions that include populations of target nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol; and the like.
Factors for selecting substrates include, for example, the material, porosity, size, and shape. Other important factors to be considered in selecting appropriate substrates include size uniformity, efficiency as a synthesis support, and the substrate's optical properties, e.g., clear smooth substrates (free from defects) provide instrumentational advantages when detecting incorporation of nucleotides in single molecules (e.g., nucleic acids.).
Substrates are coated with a surface that facilitates nucleic acid binding and that reduces background. Preferred coatings are epoxides, silanized epoxides, biotinylated epoxides, streptavidinated epoxides, polyelecrolyte multilayers, including those that are derivatized for nucleic acid attachment (e.g., biotinylated, streptavidinated, or coated with a binding partner on the template/primer.
Surfaces
Surfaces used to attach duplexes according to the invention can be any surface to which a binding partner is capable of attaching. For sequencing, surfaces should be free of debris, especially debris capable of fluorescing. Also, surfaces should be stable and transparent to light. Preferred surfaces are epoxy surfaces and polyelectrolyte multilayer surfaces. Either of those surfaces is easily derivatized as described in the art for attachment of binding pairs. For example, epoxide surfaces are derivatized with silane or other species capable of receiving binding partners. In certain embodiments, binding pair members attached to template/primer hybrids attach directly to the surface via a molecule embedded in the surface that is not the normal binding partner for the binding pair member. Polyelectrolyte multilayer surfaces are formed from a variety of alternating layers of positive and negative charge. Preferred polyelectrolyte multilayer surfaces are described in detail below.
Target Nucleic Acids
A target nucleic acid for analysis may be obtained from a patient sample, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, breast nipple aspirate, sputum, stool and biopsy tissue. Any tissue or body fluid specimen may be used according to methods of the invention.
A target nucleic acid can come from a variety of sources. For example, nucleic acids can be naturally occurring DNA or RNA isolated from any source, recombinant molecules, cDNA, or synthetic analogs, as known in the art. For example, the target nucleic acid may be genomic DNA, genes, gene fragments, exons, introns, regulatory elements (such as promoters, enhancers, initiation and termination regions, expression regulatory factors, expression controls, and other control regions), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, and other mutations. Also included is the full genome of one or more cells, for example cells from different stages of diseases such as cancer. The target nucleic acid may also be mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, or siRNA. Also contemplated according to the invention are RNA with a recognition site for binding a polymerase, transcripts of a single cell, organelle or microorganism, and all or portions of RNA complements of one or more cells, for example, cells from different stages of development or differentiation, and cells from different species. Nucleic acids can be obtained from any cell of a person, animal, plant, bacteria, or virus, including pathogenic microbes or other cellular organisms. Individual nucleic acids can be isolated for analysis.
Stabilizing Molecules and Primers
Methods of the invention also contemplate using a stabilizing molecule in a sequencing-by-synthesis reaction. The stabilizing molecule strengthens the primer/template bond and increases the specificity of incorporation of nucleotides into the primer, the melting temperature of the primer/target nucleic acid duplex, or both. A stabilizing molecule may comprise nucleotide or internucleotide analogs, or covalently bound minor groove binders or intercalators that enhance hybridization avidity or specificity of the primer to a target nucleic acid. The internucleotide analogs can comprise one or more of a phosphate ester analog such as alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates and phosphorodithioates.
In one aspect, the stabilizing molecule comprises a minor groove binder. Minor groove binders are described in detail in U.S. Pat. No. 6,084,102 which is incorporated by reference in its entirety herein. Generally, a minor groove binder has a molecular weight of approximately 150 to approximately 2000 daltons, and typically covalently attaches to at least one of the nucleotides in a duplex. It incorporates into a duplex to strengthen the template/primer bond, thus increasing hybridization stability.
In one embodiment, a stabilizing molecule may comprise a conformationally restricted nucleotide analog such as a peptide nucleic acid base, a locked nucleic acid base or an oxetane modified base (for a discussion of base constraining oxetane modifications, see U.S. Published Patent Application No. 20040142946, the disclosure of which is incorporated by reference herein). A peptide nucleic acid is a nucleic acid analog in which the backbone comprises synthetic peptide like linkages (amide bonds) usually formed from N-(2-amino-ethyl)-glycine units, resulting in an achiral and uncharged molecule. PNA hybridizes with complementary nucleic acids with high affinity and specificity, and forms PNA/DNA and PNA/RNA duplexes having greater thermal and chemical stability than counterpart DNA/DNA duplexes.
A locked nucleic acid is a bicyclic nucleic acid analog that contains one or more 2′-O, 4′-C methylene linkage(s), which effectively locks the furanose ring in a C3′-endo conformation. This methylene linkage “bridge” restricts the flexibility of the ribofuranose ring and locks the structure into a rigid bicyclic formation. Because of its unique structural conformation, locked nucleic acids demonstrate a much greater affinity and specificity to their complementary nucleic acids than do natural DNA counterparts and increases the thermal and chemical stability of a primer/target nucleic acid duplex. LNAs will hybridize to complementary nucleic acids even under adverse conditions, such as under low salt concentrations and in the presence of chaotropic agents. According to one aspect of the invention, locked nucleic acids increase the melting point of the primer/target nucleic acid duplex by about 3° to about 8° Celsius per locked nucleic acid base incorporated in the primer.
Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. Locked nucleic acid bases may be interspersed throughout a strand of a primer, as shown in
In general, primer length is selected to facilitate hybridization to a sufficiently complementary region of the template nucleic acid downstream of the region to be analyzed. The exact lengths of the primers depend on many factors, including temperature and source of primer. Placement of locked nucleic acid bases throughout a primer allows for an increased melting temperature of the primer/target nucleic acid duplex during a sequencing reaction. This also allows the primer length to remain short compared to a primer that does not contain locked nucleic acid bases. Embodiments of this invention include primers with 20 bases or less, which incorporate from 1 to 12 or more locked nucleic acid bases. For example, a 20 base primer which includes 12 locked nucleic acid bases may yield a melting temperature of between about 80° to 90° C. According to one embodiment of the invention, the primer comprises less than about 30, 25, 20, 15, 10, or 5 bases.
Primers can be synthetically made using conventional nucleic acid synthesis techniques. For example, primers are synthesized on an automated DNA synthesizer (e.g., Applied Biosystems, Inc., Foster City, Calif.) using standard chemistries, such as phosphoramidite chemistry, and the like. Alternative chemistries, e.g., resulting in non-natural backbone groups, such as phosphorothioate, phosphoramidate, and the like, may also be employed provided that, for example, the resulting oligonucleotides are compatible with the polymerizing agent. The primers can also be ordered commercially from a variety of companies which specialize in custom nucleic acids such as Operon, Inc. (Alameda, Calif.). Primers comprising locked nucleic acids are purchased commercially (Proligo® LLC, Boulder, Colo.) or prepared as needed by methods known in the art.
The foregoing methods confer a significant advantage in single molecule reactions, in which one is tracking nucleotide incorporation into individual template/primer duplexes. Single molecule techniques provide the ability to observe discrete differences within and between individuals in terms of nucleotide sequence. Disruption of a hybrid impairs the ability to obtain full advantage from single molecule techniques because the loss of a hybrid represents the loss of significant information content relative to a bulk reaction in which there exist numerous copies of each hybrid pair. Methods of the invention maximize the ability to keep hybrid pairs intact and attached to substrate.
Primer Hybridization
Conditions for hybridizing primers to target nucleic acids are known in the art. The annealing reaction is performed under conditions which are stringent enough to ensure sequence specificity, yet sufficiently permissive to allow formation of stable hybrids at an acceptable rate. The temperature and length of time required for primer annealing depend upon several factors including the base composition, length and concentration of the primer, and the nature of the solvent used, e.g., the concentration of cosolvents such as DMSO (dimethylsulfoxide), formamide, or glycerol, and counterions such as magnesium. Typically, hybridization (annealing) is carried out at a temperature that is approximately 5 to 10° Celsius below the melting temperature of the primer/target nucleic acid duplex in the annealing solvent. Annealing temperatures may be modified based on the amount of locked nucleic acid included in the primer, based on manufacturer's recommendation and methods known in the art.
Primer Extension and Labeling
During primer extension, the primer/target nucleic acid duplex is exposed to a polymerase, and at least one nucleotide or nucleotide analog under conditions that allow for incorporation of the nucleotide into the primer. Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependant addition of a nucleotide to a primer, such as, Klenow, Vent ThermoSequenase®, 9° N™, Therminator, Taq, Tfl, Tth, Tli, Pfu, and others. According to one aspect of the invention, a thermophilic polymerase is used. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius, or at least about 50°, 60°, or 70° Celsius.
Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids, oxetane-modified bases and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
Nucleotides particularly useful in the invention comprise detectable labels. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.
Other suitable fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); 5′5″-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC); eosin and derivatives; eosin, eosin isothiocyanate, erythrosin and derivatives; erythrosin B, erythrosin, isothiocyanate; ethidium; fluorescein derivatives; 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2′,7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives: pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum dots; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A) rhodamine and derivatives: 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine; tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid; terbium chelate derivatives; Cy5.5; Cy7; IRD 700; IRD 800; La Jolta Blue; phthalo cyanine; and naphthalo cyanine.
In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
Further, the primer or the target nucleic acid can also include a detectable label. When the labeled primer and/or target nucleic acid are attached to the substrate, the label facilitates locating the bound molecule through imaging. The primer or target nucleic acid can be labeled with a fluorescent labeling moiety (e.g., Cy3 or Cy5), or any other means used to label nucleotides. The detectable label used to label the primer or target nucleic acid can be different from the label used on the nucleotides or nucleotide analogs in the subsequent extension reactions. Additionally, once the molecule has been localized, it may be desirable to render the label undetectable prior to the nucleotide incorporation detection steps by methods such as washing or photobleaching.
A nucleotide analog according to the invention can be modified to remove, cap or modify the 3′ hydroxyl group. As such, in certain embodiments, methods of the invention can include, for example, the step of removing the 3′ hydroxyl group from the incorporated nucleotide or nucleotide analog. By removing the 3′ hydroxyl group from the incorporated nucleotide in the primer, further extension is halted or impeded. In certain embodiments, the modified nucleotide can be engineered so that the 3′ hydroxyl group can be removed and/or added by chemical methods. Alternatively, a nucleotide analog can be modified to include a moiety that is sufficiently large to prevent or sterically hinder further chain elongation by interfering with the polymerase, thereby halting incorporation of additional nucleotides or nucleotide analogs. Subsequent removal of the moiety, or at least the steric-hindering portion of the moiety, can concomitantly reverse chain termination and allow chain elongation to proceed. In some embodiments, the moiety also can be a label. As such, in those embodiments, chemically cleaving or photocleaving the blocking moiety may also chemically-bleach or photobleach the label, respectively.
Detection of Incorporated Nucleotides
Incorporation of a nucleotide or a nucleotide analog and their locations on the surface of a substrate can be detected with single molecule sensitivity according to the invention. In some aspects of the invention, single molecule resolution is achieved by anchoring a target nucleic acid at a low concentration to a substrate, and then imaging nucleotide incorporation with for example, with total internal reflection fluorescence microscopy.
A number of detection methods are available for use in single molecule analysis. Methods for visualizing single molecules within nucleic acids labeled with an intercalating dye include, for example, fluorescence microscopy. For example, the fluorescent spectrum and lifetime of a single molecule excited-state can be measured. Standard detectors such as a photomultiplier tube or avalanche photodiode can be used. Full field imaging with a two-stage image intensified COD camera also can be used. Additionally, low noise cooled CCD can also be used to detect single fluorescent molecules.
The detection system for the signal may depend upon the labeling moiety used, which can be defined by the chemistry available. For optical signals, a combination of an optical fiber or CCD can be used in the detection step. In the embodiments where the substrate is itself transparent to the radiation used, it is possible to have an incident light beam pass through the substrate with the detector located opposite the substrate from the primer. For electromagnetic labels, various forms of spectroscopy systems can be used. Various physical orientations for the detection system are available and known in the art.
A number of approaches can be used to detect incorporation of fluorescently-labeled nucleotides into a single molecule. Optical systems include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy. In general, methods involve detection of laser-activated fluorescence using a microscope equipped with a camera, sometimes referred to as high-efficiency photon detection system. Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras. For example, as illustrated in
Certain embodiments of the invention are described in the following examples, which are not meant to be limiting.
General methods of the invention were demonstrated using biotin/avidin binding pairs. When a biotin-streptavidin linkage is used to anchor a primer and a target nucleic acid to a substrate, the primer and target nucleic acid are biotinylated, while the surface of the substrate is coated with streptavidin. Because streptavidin is a tetramer, it is possible that both template and primer will bind to the same surface streptavidin. However, the dual biotin labels may bind to adjacent streptavidin molecules as well.
Two experiments were done to determine the binding stability of the dual biotin constructs. A first experiment was conducted in order to determine the stability of dual biotin duplex on a polyelectrolyte multilayer (PEM) surface. This experiment was done using covalent streptavidin attachment to a PEM surface. The PEM surfaces were prepared as follows. Polyethyleneimine (PEI) and pollyallylamine (PAA, Sigma, St. Louis, Mo.) were dissolved separately by stirring in MilliQ water and the pH was adjusted to 8.0 with dilute HCl. The solutions were filtered using a 0.22μ filter flask and stored at 4° C. Clean glass slides were then alternatively immersed for 10 minutes in the PEI and PAA solutions four times each with an 8 minute rinse using MilliQ water between each immersion. After the last rinse, the slides were kept immersed in water. The slides were then transferred to MES buffer (2-[N-morpholino] ethanesulfonic acid), pH 5.5 for EDC-induced crosslinking of the PEM. A 10 mM solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) was prepared in MES buffer, filtered and added to the solution containing the PEM-coated slides for 1 hour at room temperature. Slides were then rinsed in MES buffer and stored.
Next, the PEM surfaces were amine-derivatized by treatment with 10 mM NHS and 10 mM EDC in 0.1 M MES buffer, pH 6.0, OSM NaCl (coupling buffer) for 15 minutes. The surfaces were then rinsed twice in the coupling buffer and incubated for 1 hour in 0.1 mg/ml Streptavidin Plus (SA-20, Prozyme) in the coupling buffer. The resulting streptavidinated surfaces were rinsed in a 200 μl solution of dual-biotin duplex in which the primer had the sequence: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1) and the template had the sequence: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2; primer binding region bolded and underlined). At its 3′ end, the terminal thymidine was labeled with cyanine-5 dye and the adenine two positions 5′ of the terminus was labeled with a cyanine-3 dye. Surfaces were soaked for 5 minutes and then rinsed once in 20 mM Tris, pH 8.0, 50 mM NaCl, 0.01% Triton (Rinse Buffer). The surfaces were then rinsed 5 times in 3×SSC-0.1% Triton, with a 10 minute soak in the last rinse. Finally, the surfaces were rinsed in two changes of the Rinse Buffer. The resulting surface had dual-biotin primer/target nucleic acid duplex bound to streptavidin. A second set of slides was rinsed with the dual biotin duplexes as described above, but was also challenged with 100 nM unlabeled biotin. All slides were imaged over a 1000 μ2 area and analyzed in ImagePro (Media Cybernetics, San Diego) using a dark image background subtraction algorithm.
Visualization of surface-bound duplexes was accomplished using fluorescence resonance energy transfer (FRET), with the cyanine-5 labeled thymidine as the donor and the cyanine-3 labeled adenine as the acceptor. Slides were placed on a Nikon Eclipse TE-2000 inverted microscope with a total internal reflection objective. The dual-biotin duplex slides showed 309.7 counts/pixel and the biotin-challenged slides showed 10.1 counts/pixel. These results indicate that the dual-biotin duplexes were binding to streptavidin on the PEM in a specific manner, as the cold biotin was able to compete away duplex binding.
In a separate experiment, the dual biotin duplexes referred to above were first bound to a streptavidinated PEM surface as described above. The surface was then exposed to 100 nM unlabeled biotin at 52° C. for 10 minutes. As a control, streptavidinated PEMs were incubated in parallel and then rinsed with dual-biotin duplex. All slides then were washed, imaged, and analyzed as described above. The data are shown in
Another experiment shows the stability of dual-biotin duplexes in single molecule sequencing. For this experiment, streptavidinated slides are prepared on a PEM as described above. The slides then are biotinylated. Fresh biotin-long chain polyethyloxide-amine (Biotin-LC-PEO, Pierce) is prepared in MES buffer (50 mg Biotin in 2.5 ml MES). A 5 ml aliquot of the EDC solution described above is combined with 5 ml of the Biotin-LC-PEO solution and diluted in MES buffer to a total volume of 96 ml by adding 86 ml of MES buffer to a 2.5 mM final EDC-biotin concentration. The PEM-coated slides are then immersed in that solution in a 100 ml beaker and incubated for 60 minutes at room temperature. The slides are then rinsed in MES buffer with gentle agitation for 10 seconds. Immersion and rinsing are repeated four times in clean 100 ml volumes. Slides are then incubated in the final bath for 10 minutes. The resulting biotin-coated slides are stored in Tris-NaCl buffer prior to streptavidination.
Streptavidin-Plus (SA20, Prozyme) is dissolved in a solution of 10 mM NaCl buffer at 0.14 mg/ml and stirred 10 minutes at room temperature to thoroughly dissolve flakes. The resulting solution is filtered with a 0.22μ filter. Biotinylated slides described above are placed in this solution in a 100 ml beaker with a stir bar and stirred for 15 minutes at room temperature. The slides are then rinsed in 100 ml Tris-NaCl buffer with gentle agitation for 10 seconds. The rinse process is repeated 5 times in clean 100 ml volumes of 3×SSC-0.1% Triton, incubating in the final bath for 10 minutes. Finally, the slides are transferred to a fresh bath of Tris-NaCl and agitated for 10 seconds. Slides arestored in Tris-NaCl buffer at 4° C. prior to use.
3′ bioinylated target nucleic acid templates: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2), are obtained from Integrated DNA Technologies (Coral, IA). 5′ biotinylated primers: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1), comprising a cyanine-5 dye were hybridized to the templates and exposed to the streptavidinated surfaces described above at a concentration of 10 pM. After incubation for 10 minutes, the surfaces are washed with MES buffer and the surface was imaged using a Nikon TE-2000U upright microscope equipped with a total internal reflection objective (Nikon). The location of label represented the location of bound hybrid and the positions of label are noted. Positional detection can also be accomplished using unlabeled template/primer and adding labeled first base. To determine the stability of bound duplexes, nucleotide additions are accomplished using the Klenow fragment (exo-) polymerase (New England Biolabs) at 10 mM in Ecopol reaction buffer and a series of cyanine-labeled nucleotide triphosphates. To reduce bleaching of the fluorescent dyes, an oxygen scavenging system is used (glucose (0.36%), glucose oxidase (8 U/ml), catalase (423 U/ml), Trolox (5 mM), Gallate (5 mM), DABCO (10 mM), and 2,4,6-octatrienoic acid).
The positions of cyanine-5-labeled primer are recorded and bleached. dUTP-Cy3 in polymerase is added to the slides. If dUTP is incorporated into the primer, fluorescence resonance energy transfer (FRET) from the cyanine-5 on the primer will caus the cyanine-3 dye to emit and the location of the emission is detected. The cyanine-3 dye is kept unbleached and subsequent additions are with cyanine-5-labeled dNTPs, using FRET with cyanine-3 as the donor for detection of incorporation. The results show that dual-biotin duplex is a stable template for template-dependent sequencing.
The skilled artisan understands that there are numerous other embodiments of the invention in terms of surfaces, binding partners and the like that can be manipulated in order to achieve the stability results shown above.
A primer is designed to be complementary to a known primer attachment site of the target nucleic acid, and locked nucleic acid bases are substituted for certain nucleotides within the selected primer sequence. As many locked nucleic acid bases are selected as desired depending on the temperature and length of primer, up to a primer comprising 100% locked nucleic acids. The more locked nucleic acid substitutions into the primer, the greater the melting point of the primer/target nucleic acid duplex relative a primer of the same length lacking locked nucleic acid residues.
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Number | Name | Date | Kind |
---|---|---|---|
3996345 | Ullman et al. | Dec 1976 | A |
4119368 | Yamazaki | Oct 1978 | A |
4153855 | Feingold | May 1979 | A |
4344064 | Bitler et al. | Aug 1982 | A |
4351760 | Khanna et al. | Sep 1982 | A |
4683195 | Mullis et al. | Jul 1987 | A |
4683202 | Mullis | Jul 1987 | A |
4707237 | Lepp et al. | Nov 1987 | A |
4711955 | Ward et al. | Dec 1987 | A |
4725677 | Kosler et al. | Feb 1988 | A |
4739044 | Slabinskv | Apr 1988 | A |
4757141 | Fung et al. | Jul 1988 | A |
4793705 | Shera | Dec 1988 | A |
4811218 | Hunkapiller et al. | Mar 1989 | A |
4863849 | Melamede | Sep 1989 | A |
4865968 | Orgel et al. | Sep 1989 | A |
4889818 | Gelfand et al. | Dec 1989 | A |
4942124 | Church | Jul 1990 | A |
4962037 | Jett et al. | Oct 1990 | A |
4971903 | Hyman | Nov 1990 | A |
4979824 | Mathies et al. | Dec 1990 | A |
4994368 | Goodman et al. | Feb 1991 | A |
4994372 | Tabor et al. | Feb 1991 | A |
4994373 | Stavrianopoulos et al. | Feb 1991 | A |
5085562 | Van Lintel | Feb 1992 | A |
5091652 | Mathies et al. | Feb 1992 | A |
5096388 | Weinberg | Mar 1992 | A |
5096554 | Chin et al. | Mar 1992 | A |
5108892 | Burke et al. | Apr 1992 | A |
5112736 | Caldwell et al. | May 1992 | A |
RE34069 | Koster et al. | Sep 1992 | E |
5143854 | Pirrung et al. | Sep 1992 | A |
5167784 | Noolandi | Dec 1992 | A |
5171132 | Miyazaki et al. | Dec 1992 | A |
5198540 | Koster | Mar 1993 | A |
5209834 | Shera | May 1993 | A |
5224843 | Van Lintel | Jul 1993 | A |
5242796 | Prober et al. | Sep 1993 | A |
5242797 | Hirschfeld | Sep 1993 | A |
5258506 | Urdea et al. | Nov 1993 | A |
5259737 | Kamisuki et al. | Nov 1993 | A |
5260433 | Engelhardt et al. | Nov 1993 | A |
5265327 | Faris et al. | Nov 1993 | A |
5267152 | Yang et al. | Nov 1993 | A |
5302509 | Cheeseman | Apr 1994 | A |
5304487 | Wilding et al. | Apr 1994 | A |
5306403 | Vo-Dinh | Apr 1994 | A |
5336062 | Richter | Aug 1994 | A |
5360523 | Middendorf et al. | Nov 1994 | A |
5375979 | Trah | Dec 1994 | A |
5376252 | Ekstrom et al. | Dec 1994 | A |
5403709 | Agrawal et al. | Apr 1995 | A |
5405747 | Jett et al. | Apr 1995 | A |
5405783 | Pirrung et al. | Apr 1995 | A |
5409811 | Tabor et al. | Apr 1995 | A |
5424186 | Fodor et al. | Jun 1995 | A |
5436149 | Barnes | Jul 1995 | A |
5449767 | Ward et al. | Sep 1995 | A |
5476928 | Ward et al. | Dec 1995 | A |
5484701 | Cocuzza et al. | Jan 1996 | A |
5492806 | Drmanac et al. | Feb 1996 | A |
5514256 | Douthart et al. | May 1996 | A |
5518900 | Nikiforov et al. | May 1996 | A |
5525464 | Drmanac et al. | Jun 1996 | A |
5529465 | Zengerle et al. | Jun 1996 | A |
5534125 | Middendorf et al. | Jul 1996 | A |
5547839 | Dower et al. | Aug 1996 | A |
5547859 | Goodman et al. | Aug 1996 | A |
5556790 | Pettit | Sep 1996 | A |
5558991 | Trainor | Sep 1996 | A |
5599695 | Pease et al. | Feb 1997 | A |
5610287 | Nikiforov et al. | Mar 1997 | A |
5631734 | Stern et al. | May 1997 | A |
5632957 | Heller et al. | May 1997 | A |
5654149 | Mendoza et al. | Aug 1997 | A |
5659171 | Young et al. | Aug 1997 | A |
5670346 | Reeve et al. | Sep 1997 | A |
5674716 | Tabor et al. | Oct 1997 | A |
5675155 | Pentoney, Jr. et al. | Oct 1997 | A |
5688648 | Mathies et al. | Nov 1997 | A |
5695940 | Drmanac et al. | Dec 1997 | A |
5705018 | Hartley | Jan 1998 | A |
5707506 | Douthart et al. | Jan 1998 | A |
5710628 | Waterhouse et al. | Jan 1998 | A |
5712476 | Renfrew et al. | Jan 1998 | A |
5733729 | Lipshutz et al. | Mar 1998 | A |
5741640 | FuBer | Apr 1998 | A |
5741644 | Kambara et al. | Apr 1998 | A |
5744305 | Fodor et al. | Apr 1998 | A |
5744312 | Mamone et al. | Apr 1998 | A |
5750341 | Macevicz et al. | May 1998 | A |
5753788 | Fodor et al. | May 1998 | A |
5755943 | Middendorf et al. | May 1998 | A |
5756285 | Fuller | May 1998 | A |
5759014 | Van Lintel | Jun 1998 | A |
5759374 | Takahashi et al. | Jun 1998 | A |
5762876 | Lincoln et al. | Jun 1998 | A |
5763594 | Hiatt et al. | Jun 1998 | A |
5776767 | Stevens et al. | Jul 1998 | A |
5776782 | Tsuji | Jul 1998 | A |
5789168 | Leushner et al. | Aug 1998 | A |
5795722 | Lacroix et al. | Aug 1998 | A |
5795782 | Church et al. | Aug 1998 | A |
5807679 | Kamb | Sep 1998 | A |
5808045 | Hiatt et al. | Sep 1998 | A |
5830657 | Leushner et al. | Nov 1998 | A |
5831070 | Pease et al. | Nov 1998 | A |
5832165 | Reichert et al. | Nov 1998 | A |
5834758 | Trulson et al. | Nov 1998 | A |
5836750 | Cabuz | Nov 1998 | A |
5837832 | Chee et al. | Nov 1998 | A |
5837860 | Anderson et al. | Nov 1998 | A |
5846396 | Zanzucchi et al. | Dec 1998 | A |
5846727 | Soper et al. | Dec 1998 | A |
5853979 | Green et al. | Dec 1998 | A |
5858671 | Jones | Jan 1999 | A |
5861287 | Metzker et al. | Jan 1999 | A |
5863722 | Brenner | Jan 1999 | A |
5872244 | Hiatt et al. | Feb 1999 | A |
5876187 | Afomowitz | Mar 1999 | A |
5876934 | Duthie et al. | Mar 1999 | A |
5882904 | Riedl et al. | Mar 1999 | A |
5885813 | Davis et al. | Mar 1999 | A |
5889165 | Fodor et al. | Mar 1999 | A |
5902723 | Dower et al. | May 1999 | A |
5908755 | Kumar et al. | Jun 1999 | A |
5916747 | Gilchrist et al. | Jun 1999 | A |
5922591 | Anderson et al. | Jul 1999 | A |
5922608 | Farnsworth et al. | Jul 1999 | A |
5928906 | Koster et al. | Jul 1999 | A |
5928919 | Reha-Krantz et al. | Jul 1999 | A |
5945283 | Kwok et al. | Aug 1999 | A |
5945284 | Livak et al. | Aug 1999 | A |
5945312 | Goodman et al. | Aug 1999 | A |
5945325 | Arnold et al. | Aug 1999 | A |
5948614 | Chatterjee | Sep 1999 | A |
5952174 | Nikiforov et al. | Sep 1999 | A |
5954932 | Takahashi et al. | Sep 1999 | A |
5958703 | Dower et al. | Sep 1999 | A |
5959781 | Kintz et al. | Sep 1999 | A |
5959837 | Yu | Sep 1999 | A |
5965446 | Ishikawa | Oct 1999 | A |
5968740 | Fodor et al. | Oct 1999 | A |
5974164 | Chee | Oct 1999 | A |
5976338 | Fujita et al. | Nov 1999 | A |
5981186 | Gabe et al. | Nov 1999 | A |
5981956 | Stern | Nov 1999 | A |
5994058 | Senapathy | Nov 1999 | A |
5994085 | Cantor | Nov 1999 | A |
6002471 | Quake | Dec 1999 | A |
6005663 | Waterhouse et al. | Dec 1999 | A |
6007309 | Hartley | Dec 1999 | A |
6015714 | Baldarelli et al. | Jan 2000 | A |
6017702 | Lee et al. | Jan 2000 | A |
6018041 | Drmanac et al. | Jan 2000 | A |
6020457 | Klimash et al. | Feb 2000 | A |
6024925 | Little et al. | Feb 2000 | A |
6025136 | Drmanac | Feb 2000 | A |
6028190 | Mathies et al. | Feb 2000 | A |
6030782 | Anderson et al. | Feb 2000 | A |
6043080 | Lipshutz et al. | Mar 2000 | A |
6046005 | Ju et al. | Apr 2000 | A |
6049380 | Goodwin et al. | Apr 2000 | A |
6051380 | Sosnowski et al. | Apr 2000 | A |
6066454 | Lipshutz et al. | May 2000 | A |
6071394 | Cheng et al. | Jun 2000 | A |
6077664 | Slater et al. | Jun 2000 | A |
6077674 | Schleifer et al. | Jun 2000 | A |
6087095 | Rosenthal et al. | Jul 2000 | A |
6087099 | Gupte et al. | Jul 2000 | A |
6094274 | Yokoi | Jul 2000 | A |
6107032 | Kilger et al. | Aug 2000 | A |
6107044 | Nikiforov | Aug 2000 | A |
6107061 | Johnson | Aug 2000 | A |
6132580 | Mathies et al. | Oct 2000 | A |
6133436 | Koster et al. | Oct 2000 | A |
6136212 | Mastrangelo et al. | Oct 2000 | A |
6136962 | Shi et al. | Oct 2000 | A |
6140053 | Koster | Oct 2000 | A |
6140494 | Hamilton et al. | Oct 2000 | A |
6141096 | Stern et al. | Oct 2000 | A |
6143151 | Middendorf et al. | Nov 2000 | A |
6147205 | McGall et al. | Nov 2000 | A |
6156501 | McGall et al. | Dec 2000 | A |
6165694 | Liu | Dec 2000 | A |
6177249 | Kwok et al. | Jan 2001 | B1 |
6197506 | Fodor et al. | Mar 2001 | B1 |
6197595 | Anderson et al. | Mar 2001 | B1 |
6207381 | Larsson et al. | Mar 2001 | B1 |
6207960 | Stern | Mar 2001 | B1 |
6210896 | Chan | Apr 2001 | B1 |
6214246 | Craighead | Apr 2001 | B1 |
6214987 | Hiatt et al. | Apr 2001 | B1 |
6221592 | Schwartz et al. | Apr 2001 | B1 |
6221654 | Quake et al. | Apr 2001 | B1 |
6225052 | Batz et al. | May 2001 | B1 |
6225062 | Dunn et al. | May 2001 | B1 |
6225092 | Kilger et al. | May 2001 | B1 |
6225109 | Juncosa et al. | May 2001 | B1 |
6225567 | Kester | May 2001 | B1 |
6225625 | Pirrung et al. | May 2001 | B1 |
6228593 | Lipshutz et al. | May 2001 | B1 |
6232075 | Williams | May 2001 | B1 |
6232103 | Short | May 2001 | B1 |
6235465 | Kolberg et al. | May 2001 | B1 |
6235473 | Friedman et al. | May 2001 | B1 |
6242180 | Chee | Jun 2001 | B1 |
6242528 | Clark et al. | Jun 2001 | B1 |
6245506 | Laugharn, Jr. et al. | Jun 2001 | B1 |
6245507 | Bogdanov | Jun 2001 | B1 |
6245518 | Baier | Jun 2001 | B1 |
6251610 | Gupte et al. | Jun 2001 | B1 |
6255083 | Williams | Jul 2001 | B1 |
6255475 | Kwiatkowski | Jul 2001 | B1 |
6258533 | Jones | Jul 2001 | B1 |
6261775 | Bastian et al. | Jul 2001 | B1 |
6261776 | Pirrung et al. | Jul 2001 | B1 |
6261848 | Anderson et al. | Jul 2001 | B1 |
6262838 | Montagu | Jul 2001 | B1 |
6263286 | Gilmanshin et al. | Jul 2001 | B1 |
6268152 | Fodor et al. | Jul 2001 | B1 |
6268219 | Mcbride et al. | Jul 2001 | B1 |
6269846 | Overbeck et al. | Aug 2001 | B1 |
6270644 | Mathies et al. | Aug 2001 | B1 |
6270961 | Drmanac | Aug 2001 | B1 |
6274320 | Rothberg et al. | Aug 2001 | B1 |
6274351 | Peponnet | Aug 2001 | B1 |
6277604 | Peponnet | Aug 2001 | B1 |
6280954 | Ulfendahl | Aug 2001 | B1 |
6284460 | Fodor et al. | Sep 2001 | B1 |
6287821 | Shi et al. | Sep 2001 | B1 |
6294336 | Boyce-Jacino et al. | Sep 2001 | B1 |
6294337 | Hayashizaki | Sep 2001 | B1 |
6306607 | Williams | Oct 2001 | B2 |
6309601 | Juncosa et al. | Oct 2001 | B1 |
6309701 | Barbera-Guillem | Oct 2001 | B1 |
6309824 | Drmanac | Oct 2001 | B1 |
6309836 | Kwiatkowski | Oct 2001 | B1 |
6309886 | Ambrose et al. | Oct 2001 | B1 |
6310189 | Fodor et al. | Oct 2001 | B1 |
6312893 | Van Ness et al. | Nov 2001 | B1 |
6316191 | Drmanac et al. | Nov 2001 | B1 |
6322968 | Head et al. | Nov 2001 | B1 |
6331439 | Cherukuri et al. | Dec 2001 | B1 |
6333183 | Evans et al. | Dec 2001 | B1 |
6335824 | Overbeck | Jan 2002 | B1 |
6337185 | Asp et al. | Jan 2002 | B1 |
6337188 | Head et al. | Jan 2002 | B1 |
6342326 | Milton | Jan 2002 | B1 |
6344325 | Quake et al. | Feb 2002 | B1 |
6346379 | Gelfand et al. | Feb 2002 | B1 |
6346413 | Fodor et al. | Feb 2002 | B1 |
6355420 | Chan | Mar 2002 | B1 |
6355432 | Fodor et al. | Mar 2002 | B1 |
6361671 | Mathies et al. | Mar 2002 | B1 |
6361937 | Stryer | Mar 2002 | B1 |
6368562 | Yao | Apr 2002 | B1 |
6368699 | Gilbert et al. | Apr 2002 | B1 |
6383749 | Bochkariov et al. | May 2002 | B2 |
6387626 | Shi et al. | May 2002 | B1 |
6395232 | McBride | May 2002 | B1 |
6395559 | Swenson | May 2002 | B1 |
6397150 | Izmailov | May 2002 | B1 |
6399364 | Reeve et al. | Jun 2002 | B1 |
6401267 | Drmanac | Jun 2002 | B1 |
6403311 | Chan | Jun 2002 | B1 |
6403315 | Drmanac | Jun 2002 | B1 |
6403317 | Anderson | Jun 2002 | B1 |
6403320 | Read et al. | Jun 2002 | B1 |
6403957 | Fodor et al. | Jun 2002 | B1 |
6404907 | Gilchrist et al. | Jun 2002 | B1 |
6406893 | Knapp et al. | Jun 2002 | B1 |
6407858 | Montagu | Jun 2002 | B1 |
6408878 | Unger et al. | Jun 2002 | B2 |
6416952 | Pirrung et al. | Jul 2002 | B1 |
6420169 | Read et al. | Jul 2002 | B1 |
6423273 | O'Mara | Jul 2002 | B1 |
6432634 | Digby et al. | Aug 2002 | B1 |
6436641 | Izmailov | Aug 2002 | B1 |
6436646 | Nikiforov | Aug 2002 | B1 |
6440664 | Digby et al. | Aug 2002 | B1 |
6440722 | Knapp et al. | Aug 2002 | B1 |
6444106 | Mcbride et al. | Sep 2002 | B1 |
6444173 | Sjursen et al. | Sep 2002 | B1 |
6444424 | Chatterjee et al. | Sep 2002 | B1 |
6444461 | Knapp et al. | Sep 2002 | B1 |
6447724 | Jensen et al. | Sep 2002 | B1 |
6448090 | McBride | Sep 2002 | B1 |
6451536 | Fodor et al. | Sep 2002 | B1 |
6479267 | Davis et al. | Nov 2002 | B1 |
6485690 | Pfost et al. | Nov 2002 | B1 |
6485909 | Hong et al. | Nov 2002 | B1 |
6485944 | Church et al. | Nov 2002 | B1 |
6495363 | Bogdanov | Dec 2002 | B2 |
6506560 | Hughes et al. | Jan 2003 | B1 |
6511803 | Church et al. | Jan 2003 | B1 |
6514706 | Von Kalle et al. | Feb 2003 | B1 |
6521428 | Senapathy | Feb 2003 | B1 |
6524829 | Seeger | Feb 2003 | B1 |
6528258 | Russell | Mar 2003 | B1 |
6528288 | Senapathy | Mar 2003 | B2 |
6537755 | Drmanac | Mar 2003 | B1 |
6537757 | Langmore et al. | Mar 2003 | B1 |
6546340 | Lipshutz et al. | Apr 2003 | B2 |
6551784 | Fodor et al. | Apr 2003 | B2 |
6551817 | Besemer et al. | Apr 2003 | B2 |
6554987 | Gilchrist et al. | Apr 2003 | B1 |
6555349 | O'Donnell | Apr 2003 | B1 |
6558945 | Kao | May 2003 | B1 |
6562566 | Hoheisel | May 2003 | B1 |
6566059 | Stanton, Jr. et al. | May 2003 | B1 |
6566515 | McGall et al. | May 2003 | B1 |
6573047 | Hung et al. | Jun 2003 | B1 |
6573374 | Muehleger et al. | Jun 2003 | B1 |
6576424 | Fodor et al. | Jun 2003 | B2 |
6576425 | McGall et al. | Jun 2003 | B2 |
6579704 | Short | Jun 2003 | B2 |
6582923 | Stanton, Jr. et al. | Jun 2003 | B2 |
6585939 | Dapprich | Jul 2003 | B1 |
6607888 | Schwartz et al. | Aug 2003 | B2 |
6610482 | Fodor et al. | Aug 2003 | B1 |
6613513 | Parco et al. | Sep 2003 | B1 |
6623928 | Van Ness et al. | Sep 2003 | B2 |
6627748 | Ju et al. | Sep 2003 | B1 |
6632655 | Mehta et al. | Oct 2003 | B1 |
6642001 | Bolk et al. | Nov 2003 | B1 |
6664079 | Ju et al. | Dec 2003 | B2 |
6719868 | Schueller et al. | Apr 2004 | B1 |
6750018 | Kambara et al. | Jun 2004 | B2 |
6762048 | Williams | Jul 2004 | B2 |
6780591 | Williams et al. | Aug 2004 | B2 |
6783938 | Nygren et al. | Aug 2004 | B2 |
6787308 | Balasubramanian et al. | Sep 2004 | B2 |
6818395 | Quake et al. | Nov 2004 | B1 |
6908736 | Densham | Jun 2005 | B1 |
6911345 | Quake et al. | Jun 2005 | B2 |
20010024790 | Kambara et al. | Sep 2001 | A1 |
20010044531 | McGall et al. | Nov 2001 | A1 |
20010046681 | Senapathy | Nov 2001 | A1 |
20020009744 | Bogdanov | Jan 2002 | A1 |
20020012910 | Weiss et al. | Jan 2002 | A1 |
20020015961 | Kwiatkowski | Feb 2002 | A1 |
20020025529 | Quake et al. | Feb 2002 | A1 |
20020032320 | Burgess et al. | Mar 2002 | A1 |
20020034792 | Kilger et al. | Mar 2002 | A1 |
20020039738 | Williams et al. | Apr 2002 | A1 |
20020042112 | Koster et al. | Apr 2002 | A1 |
20020045182 | Singh et al. | Apr 2002 | A1 |
20020051992 | Bridgham et al. | May 2002 | A1 |
20020053532 | Quake et al. | May 2002 | A1 |
20020061529 | Bridgham et al. | May 2002 | A1 |
20020072055 | Jones | Jun 2002 | A1 |
20020086318 | Manalis et al. | Jul 2002 | A1 |
20020102586 | Ju et al. | Aug 2002 | A1 |
20020102595 | Davis | Aug 2002 | A1 |
20020106673 | Drmanac et al. | Aug 2002 | A1 |
20020115076 | Williams | Aug 2002 | A1 |
20020115092 | Rebek, Jr. | Aug 2002 | A1 |
20020119484 | Weidenhammer et al. | Aug 2002 | A1 |
20020123046 | Smith et al. | Sep 2002 | A1 |
20020132245 | Boles et al. | Sep 2002 | A1 |
20020137046 | Koster | Sep 2002 | A1 |
20020137052 | Bridgham et al. | Sep 2002 | A1 |
20020137062 | Williams et al. | Sep 2002 | A1 |
20020138205 | Miller et al. | Sep 2002 | A1 |
20020142329 | Matray et al. | Oct 2002 | A1 |
20020142333 | Gelfand et al. | Oct 2002 | A1 |
20020146704 | Head et al. | Oct 2002 | A1 |
20020146726 | Matray et al. | Oct 2002 | A1 |
20020150903 | Koster | Oct 2002 | A1 |
20020150938 | Kneipp et al. | Oct 2002 | A1 |
20020164629 | Quake et al. | Nov 2002 | A1 |
20020168642 | Drukier | Nov 2002 | A1 |
20020168678 | Williams et al. | Nov 2002 | A1 |
20020172948 | Perlin | Nov 2002 | A1 |
20020177129 | Paabo et al. | Nov 2002 | A1 |
20020182601 | Sampson et al. | Dec 2002 | A1 |
20020192661 | Paabo et al. | Dec 2002 | A1 |
20020192662 | Boyce-Jacino et al. | Dec 2002 | A1 |
20020192691 | Drmanac | Dec 2002 | A1 |
20020197618 | Sampson | Dec 2002 | A1 |
20030003272 | Laguitton | Jan 2003 | A1 |
20030003490 | Fan et al. | Jan 2003 | A1 |
20030003498 | Digby et al. | Jan 2003 | A1 |
20030008285 | Fischer | Jan 2003 | A1 |
20030008413 | Kim et al. | Jan 2003 | A1 |
20030017461 | Singh et al. | Jan 2003 | A1 |
20030022207 | Balasubramanian et al. | Jan 2003 | A1 |
20030027140 | Ju et al. | Feb 2003 | A1 |
20030036080 | Jensen et al. | Feb 2003 | A1 |
20030044778 | Goelet et al. | Mar 2003 | A1 |
20030044779 | Goelet et al. | Mar 2003 | A1 |
20030044781 | Korlach et al. | Mar 2003 | A1 |
20030044816 | Denison et al. | Mar 2003 | A1 |
20030054181 | Swerdlow et al. | Mar 2003 | A1 |
20030054361 | Heller | Mar 2003 | A1 |
20030058440 | Scott et al. | Mar 2003 | A1 |
20030058799 | Yamakawa et al. | Mar 2003 | A1 |
20030059778 | Berlin et al. | Mar 2003 | A1 |
20030060431 | Simmonds et al. | Mar 2003 | A1 |
20030064366 | Hardin et al. | Apr 2003 | A1 |
20030064398 | Barnes | Apr 2003 | A1 |
20030064483 | Shaw et al. | Apr 2003 | A1 |
20030087237 | Hong et al. | May 2003 | A1 |
20030087300 | Knapp et al. | May 2003 | A1 |
20030092005 | Levene et al. | May 2003 | A1 |
20030092007 | Gibbs et al. | May 2003 | A1 |
20030096258 | Fu et al. | May 2003 | A1 |
20030100006 | Senapathy | May 2003 | A1 |
20030104437 | Barnes et al. | Jun 2003 | A1 |
20030104466 | Knapp et al. | Jun 2003 | A1 |
20030108867 | Chee et al. | Jun 2003 | A1 |
20030138809 | Williams et al. | Jul 2003 | A1 |
20030147344 | Rothberg et al. | Aug 2003 | A1 |
20030162213 | Fuller et al. | Aug 2003 | A1 |
20030186227 | Balasubramanian et al. | Oct 2003 | A1 |
20030186255 | Williams et al. | Oct 2003 | A1 |
20030190627 | Zhao et al. | Oct 2003 | A1 |
20030190647 | Odera | Oct 2003 | A1 |
20030190663 | Yang et al. | Oct 2003 | A1 |
20030194722 | Odedra et al. | Oct 2003 | A1 |
20030194740 | Williams | Oct 2003 | A1 |
20030215862 | Wallace et al. | Nov 2003 | A1 |
20040009487 | Kadushin et al. | Jan 2004 | A1 |
20040014096 | Anderson et al. | Jan 2004 | A1 |
20040029115 | Dower et al. | Feb 2004 | A9 |
20040038206 | Zhang et al. | Feb 2004 | A1 |
20040054162 | Hanna | Mar 2004 | A1 |
20040096853 | Mayer | May 2004 | A1 |
20040106110 | Balasubramanian et al. | Jun 2004 | A1 |
20040126770 | Kumar et al. | Jul 2004 | A1 |
20050014175 | Quake et al. | Jan 2005 | A1 |
20050100932 | Lapidus et al. | May 2005 | A1 |
20050116262 | Lapidus | Jun 2005 | A1 |
20050147992 | Quake et al. | Jul 2005 | A1 |
20050170367 | Quake et al. | Aug 2005 | A1 |
20050239085 | Buzby et al. | Oct 2005 | A1 |
Number | Date | Country |
---|---|---|
10256898 | Sep 2004 | DE |
0223618 | May 1987 | EP |
0412883 | Feb 1991 | EP |
0579997 | Jan 1994 | EP |
0703364 | Mar 1996 | EP |
0706004 | Apr 1996 | EP |
0779436 | Jun 1997 | EP |
0845603 | Jun 1998 | EP |
0932700 | Aug 1999 | EP |
0946752 | Oct 1999 | EP |
0955085 | Nov 1999 | EP |
0999055 | May 2000 | EP |
0706004 | Aug 2003 | EP |
2155152 | Sep 1985 | GB |
2308460 | Jun 1997 | GB |
2400518 | Oct 2004 | GB |
9500589 | Feb 1995 | SE |
8903432 | Apr 1989 | WO |
8909283 | Oct 1989 | WO |
9013666 | Nov 1990 | WO |
9015070 | Dec 1990 | WO |
9106678 | May 1991 | WO |
9210092 | Jun 1992 | WO |
9210587 | Jun 1992 | WO |
9305183 | Mar 1993 | WO |
9306121 | Apr 1993 | WO |
9321340 | Oct 1993 | WO |
9512608 | May 1995 | WO |
9527080 | Oct 1995 | WO |
9604547 | Feb 1996 | WO |
9612014 | Apr 1996 | WO |
9612039 | Apr 1996 | WO |
9627025 | Sep 1996 | WO |
9702488 | Jan 1997 | WO |
9722076 | Jun 1997 | WO |
9723650 | Jun 1997 | WO |
9737041 | Oct 1997 | WO |
9739150 | Oct 1997 | WO |
9740184 | Oct 1997 | WO |
9741258 | Nov 1997 | WO |
9741259 | Nov 1997 | WO |
9742348 | Nov 1997 | WO |
9800708 | Jan 1998 | WO |
9802575 | Jan 1998 | WO |
9803684 | Jan 1998 | WO |
9807069 | Feb 1998 | WO |
9813523 | Apr 1998 | WO |
9808978 | May 1998 | WO |
9820019 | May 1998 | WO |
9820020 | May 1998 | WO |
9820166 | May 1998 | WO |
9821361 | May 1998 | WO |
9827228 | Jun 1998 | WO |
9828440 | Jul 1998 | WO |
9833939 | Aug 1998 | WO |
9840520 | Sep 1998 | WO |
9841650 | Sep 1998 | WO |
9841657 | Sep 1998 | WO |
9844152 | Oct 1998 | WO |
9845481 | Oct 1998 | WO |
9853300 | Nov 1998 | WO |
9854669 | Dec 1998 | WO |
9855593 | Dec 1998 | WO |
9901768 | Jan 1999 | WO |
9905221 | Feb 1999 | WO |
9905315 | Feb 1999 | WO |
9906422 | Feb 1999 | WO |
9913109 | Mar 1999 | WO |
9913110 | Mar 1999 | WO |
9909616 | Apr 1999 | WO |
9917093 | Apr 1999 | WO |
9919516 | Apr 1999 | WO |
9924797 | May 1999 | WO |
9927137 | Jun 1999 | WO |
9931278 | Jun 1999 | WO |
9937810 | Jul 1999 | WO |
9939001 | Aug 1999 | WO |
9940105 | Aug 1999 | WO |
9940223 | Aug 1999 | WO |
9941410 | Aug 1999 | WO |
0030591 | Sep 1999 | WO |
9944045 | Sep 1999 | WO |
9945153 | Sep 1999 | WO |
9947539 | Sep 1999 | WO |
9947706 | Sep 1999 | WO |
9953423 | Oct 1999 | WO |
9957321 | Nov 1999 | WO |
9961888 | Dec 1999 | WO |
9964437 | Dec 1999 | WO |
9964840 | Dec 1999 | WO |
9965938 | Dec 1999 | WO |
9966076 | Dec 1999 | WO |
9966313 | Dec 1999 | WO |
0000637 | Jan 2000 | WO |
0006770 | Feb 2000 | WO |
0009753 | Feb 2000 | WO |
0011223 | Mar 2000 | WO |
0017397 | Mar 2000 | WO |
0026935 | May 2000 | WO |
0034523 | Jun 2000 | WO |
0037680 | Jun 2000 | WO |
0040750 | Jul 2000 | WO |
0040758 | Jul 2000 | WO |
0042223 | Jul 2000 | WO |
0043540 | Jul 2000 | WO |
0043752 | Jul 2000 | WO |
0050642 | Aug 2000 | WO |
0053805 | Sep 2000 | WO |
0053812 | Sep 2000 | WO |
0056937 | Sep 2000 | WO |
0058507 | Oct 2000 | WO |
0058516 | Oct 2000 | WO |
0068410 | Nov 2000 | WO |
0070073 | Nov 2000 | WO |
0071755 | Nov 2000 | WO |
0079007 | Dec 2000 | WO |
01001025 | Jan 2001 | WO |
0116375 | Mar 2001 | WO |
0123610 | Apr 2001 | WO |
0124937 | Apr 2001 | WO |
0125480 | Apr 2001 | WO |
0131055 | May 2001 | WO |
0132930 | May 2001 | WO |
0138574 | May 2001 | WO |
0148184 | May 2001 | WO |
0142496 | Jun 2001 | WO |
0157248 | Aug 2001 | WO |
0157249 | Aug 2001 | WO |
0161044 | Aug 2001 | WO |
0164838 | Sep 2001 | WO |
0175154 | Oct 2001 | WO |
0179536 | Oct 2001 | WO |
0185991 | Nov 2001 | WO |
0192284 | Dec 2001 | WO |
0196607 | Dec 2001 | WO |
0200343 | Jan 2002 | WO |
0202584 | Jan 2002 | WO |
0202795 | Jan 2002 | WO |
0202813 | Jan 2002 | WO |
0203305 | Jan 2002 | WO |
0204680 | Jan 2002 | WO |
0220836 | Mar 2002 | WO |
0220837 | Mar 2002 | WO |
0227032 | Apr 2002 | WO |
0229106 | Apr 2002 | WO |
02030486 | Apr 2002 | WO |
0235441 | May 2002 | WO |
0236832 | May 2002 | WO |
0244414 | Jun 2002 | WO |
02061126 | Aug 2002 | WO |
02061127 | Aug 2002 | WO |
02072779 | Sep 2002 | WO |
02072892 | Sep 2002 | WO |
02077694 | Oct 2002 | WO |
02079519 | Oct 2002 | WO |
02088381 | Nov 2002 | WO |
02088382 | Nov 2002 | WO |
02097113 | Dec 2002 | WO |
02099398 | Dec 2002 | WO |
03002767 | Jan 2003 | WO |
03016565 | Feb 2003 | WO |
03021010 | Feb 2003 | WO |
03020895 | Mar 2003 | WO |
03020968 | Mar 2003 | WO |
03031947 | Apr 2003 | WO |
03044678 | May 2003 | WO |
03048178 | Jun 2003 | WO |
03048991 | Jun 2003 | WO |
03062897 | Jul 2003 | WO |
03106642 | Dec 2003 | WO |
04061119 | Jul 2004 | WO |
04074503 | Sep 2004 | WO |
05047523 | May 2005 | WO |
05080605 | Sep 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20060147942 A1 | Jul 2006 | US |